Tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

How we dress, where we go, what we search for and what we buy in 2025 says it all. And while most trends are living on borrowed time of days or weeks — maybe months if they’re lucky — a select few ...

A pair of Chinese manufacturers whose active pharmaceutical ingredients (API) were previously shipped to the U.S. | The FDA ...

The number of clinical trials in which AI designed or repurposed molecules, or targeted diseases, has more than doubled since ...

Deborah McElhone, Head of Sustainability (Pharma) from CPI, argues that process intensification is a game changer for the ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, ...

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

The grants have been the source of new treatments for cancer, heart disease, diabetes, strokes and H.I.V.; wonder drugs like ...

Researchers at Rice University have developed a new method for performing chemical reactions using water instead of toxic ...

“Companies are realizing that investing stateside can provide more control and resilience to the drug supply chain,” says Dymowski. She cites political tensions, import and export disruptions, and ...